Company Overview and News
KUALA LUMPUR, Oct 3 ― Share prices on Bursa Malaysia were slightly higher at the opening, boosted by some buying support in selected heavyweights despite the mixed performance seen on Asian share markets.
PBLOF 9318 7206 7036 1295 BSMAF HIPEF 1818 5199
KUALA LUMPUR: Tenders for floating production storage and offloading (FPSO) jobs are now at the highest in three years, Yinson Holdings Bhd group chief executive officer (CEO) Lim Chern Yuan said, adding that this bodes well for the offshore production and support services provider.
7293 7206 FXPL
KUALA LUMPUR (July 12): Tenders for floating production, storage and offloading (FPSO) jobs are now at the highest in three years, Yinson Holdings Bhd group chief executive officer Lim Chern Yuan said, adding that this bodes well for the offshore production and support services provider.
7293 7206 FXPL
PETALING JAYA: Lembaga Tabung Haji (LTH) has announced that group managing director and CEO Datuk Seri Johan Abdullah (pic) and deputy CEO Datuk Badlisyah Abdul Ghani have completed their two-year contract of service on June 30, 2018.
KUALA LUMPUR (July 4): The FBM KLCI is expected to trend lower today in line with the weaker overnight close at most global markets as mounting concerns over the a U.S.-China trade spat keeps investors on tenterhooks.
6912 4995 4863 5225 5150 7206 0082 MYTEF Q0F IHHHF 3484
KUALA LUMPUR (July 3): Based on the corporate announcements and news flow today, companies in focus on Wednesday (July 4) may include: Pasdec, Damansara Realty, TM, Green Packet, Velesto, IHH, Versatile Creative, Sunway, Zelan, Multi Sports, Lion Industries and TH Heavy Engineering.
0082 532843 3484 6912 4995 4863 5225 7206 FORTIS MYTEF Q0F BSMAF IHHHF 1818
Yinson Holdings Bhd (June 29, RM4.58) Maintain buy with a fair value (FV) of RM5.53: We maintain a buy on Yinson Holdings (Yinson) with a slightly higher sum-of-parts-based (SOP) fair value of RM5.53/share (from an earlier RM5.51/share), which implies 14 times price-earnings for the financial year ending Jan 31 2021 forecast (FY21F).
7293 7206 FXPL 7277
KUALA LUMPUR (July 2): The FBM KLCI remained subdued at mid-morning today after data showed business conditions across Malaysia’s manufacturing sector deteriorating albeit at a slower pace in June.
7052 PBLOF BATS 4162 1295 3794 2089 7077 5199 DKSHY KLKBY 3867 7206 HIPEF 5908 SPMXF UPBMF 8133 1481 5139 2445 4588 SPMXY 0026 0900 5819 DKSHF
The steady recovery in crude oil prices over the past one year has yet to have a big positive impact on OGSE players. This is partly because oil majors have yet to increase their capex in a big way.
RDS.B RDS.A XOM RDSB RDSA 8133 5255 9466 BHI 7206 5703 RYDBF RYDAF BSMAF 1818
KUALA LUMPUR: Luxchem Corp Bhd , Lotte Chemical Titan Holding Bhd, Yinson Holdings Bhd , Censof Holdings Bhd and Bintulu Port Holdings Bhd are among the stocks to watch on Wednesday, according to JF Apex Research.
7293 7206 5032 5195
KUALA LUMPUR: TH Heavy Engineering Bhd ’s shares tumbled 13% in early trade after external auditors warned of its ability to continue as a going concern.
Steady path: Gas prices are displayed at a Mobil station in New York. Crude oil prices have risen steadily by more than 10. Shares in oil majors, including Exxon Mobil, have surged. — AP
7293 7251 RDS.B RDS.A BRDBF XOM 5141 RDSB RDSA 7164 5210 0047 7206 7108 RYDBF RYDAF
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...